The effect of sacubitril/valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Failure Associations of the Polish Cardiac Society.

The effect of sacubitril/valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Failure Associations of the Polish Cardiac Society. Kardiol Pol. 2019 Sep 17;: Authors: Grabowski M, Ozierański K, Balsam P, Dąbrowski R, Farkowski MM, Gackowski A, Jędrzejczyk-Patej E, Kalarus Z, Leszek P, Nessler J, Sterliński M, Opolski G, Przybylski A Abstract Exacerbation of chronic heart failure (HF) is the most common cause of hospitalization in adults, which is associated with high morbidity and mortality, mainly in the mechanism of exacerbation of chronic HF or sudden cardiac death (SCD). A novelty in the treatment of HF with reduced left ventricular ejection fraction (HFrEF) in recent years has been registration of sacubitril/valsartan - a drug belonging to the angiotensin II receptor and neprilysin inhibitors (ARNI). Sacubitril/valsartan significantly reduces the severity of HF symptoms, the risk of hospitalization and death and is characterized by a good safety profile, due to which it has a strong position in the guidelines of international cardiac societies. However, the precise mechanism in which ARNI has a beneficial effect on cardiovascular mortality is not known. The advantages of ARNI are likely to result from improvement of left ventricle ejection fraction, reduced ...
Source: Polish Heart Journal - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research